CREATE-X a role for capecitabine in early-stage breast cancer: an analysis of available data
Abstract Breast cancer patients with residual disease after neoadjuvant chemotherapy and surgery may benefit from additional anti-cancer therapies. Capecitabine, an oral antimetabolite and prodrug of 5-Flurouracil, has been approved for treating metastatic breast cancer. One randomized clinical tria...
Guardado en:
Autores principales: | Jo Anne Zujewski, Lawrence Rubinstein |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2017
|
Materias: | |
Acceso en línea: | https://doaj.org/article/e9264fc7d1f847c1825dcf1a2d935aed |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Disparities in contralateral prophylactic mastectomy use among women with early-stage breast cancer
por: Younji Kim, et al.
Publicado: (2017) -
Inflammation of mammary adipose tissue occurs in overweight and obese patients exhibiting early-stage breast cancer
por: Charlotte Vaysse, et al.
Publicado: (2017) -
Surrogate endpoints for early-stage breast cancer: a review of the state of the art, controversies, and future prospects
por: María Gion, et al.
Publicado: (2021) -
Collagen fiber orientation disorder from H&E images is prognostic for early stage breast cancer: clinical trial validation
por: Haojia Li, et al.
Publicado: (2021) -
The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data
por: Natansh D. Modi, et al.
Publicado: (2021)